Oruka Therapeutics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Oruka Therapeutics reported Q2 2026 financial results with $1.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, expected to fund operations through an anticipated BLA filing for ORKA-001. The company advanced its pipeline: EVERLAST-B (Phase 2b, ORKA-001 in psoriasis) completed enrollment of 187 subjects with Week 16 data expected in Q4 2026; ORCA-SPLASH (Phase 2, ORKA-002 in hidradenitis suppurativa) was initiated with ~160 participants; and ORKA-004 (targeting TL1A) is expected to enter the clinic in Q4 2026. Q2 net loss was $41.2 million versus $24.6 million in Q2 2025, with R&D expenses of $43.3 million versus $24.1 million year-over-year.
Why this rating
Strong cash position ($1.1B) de-risks near-term operations; multiple clinical catalysts ahead are positive. However, net losses accelerated 68% YoY ($41M vs $25M), consuming cash despite recent $700M financing. Relative to $371.5M market cap, $1.1B cash is 3x oversubscription—unusual but not transformational without successful trial outcomes. Development stage; clinical data will drive valuation.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.